Daniel Razansky

Daniel Razansky

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2010 in Chemical Reviews
Verified
Journal Article
Closed access
VNVasilis Ntziachristos
Vasilis Ntziachristos
DRDaniel Razansky
Daniel Razansky

21 June 2009 in Nature Photonics
Verified
Journal Article
Closed access
DRDaniel Razansky
Daniel Razansky
MDMartin Distel
Martin Distel
CVClaudio Vinegoni
Claudio Vinegoni
RMRui Ma
Rui Ma
NPNorbert Perrimon
Norbert Perrimon
VNVasilis Ntziachristos
Vasilis Ntziachristos

3 March 2010 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
Sonu BhaskarSonu Bhaskar
Sonu Bhaskar
Furong TianFurong Tian
Furong Tian
TSTobias Stöger
Tobias Stöger
WKWolfgang Kreyling
Wolfgang Kreyling
Jesus M De La FuenteJesus M De La Fuente
Jesus M De La Fuente
DRDaniel Razansky
Daniel Razansky
Nanotechnology has brought a variety of new possibilities into biological discovery and clinical practice. In particular, nano-scaled carriers have revolutionalized drug delivery, allowing for therapeutic agents to be selectively targeted on an organ, tissue and cell specific level, also minimizing exposure of healthy tissue to drugs. In this review we discuss and analyze three issues, which are considered to be at the core of nano-scaled drug delivery systems, namely functionalization of nanocarriers, delivery to target organs andin vivoimaging. The latest developments on highly specific conjugation strategies that are used to attach biomolecules to the surface of nanoparticles (NP) are first reviewed. Besides drug carrying capabilities, the functionalization of nanocarriers also facilitate their transport to primary target organs. We highlight the leading advantage of nanocarriers, i.e. their ability to cross the blood-brain barrier (BBB), a tightly packed layer of endothelial cells surrounding the brain that prevents high-molecular weight molecules from entering the brain. The BBB has several transport molecules such as growth factors, insulin and transferrin that can potentially increase the efficiency and kinetics of brain-targeting nanocarriers. Potential treatments for common neurological disorders, such as stroke, tumours and Alzheimer's, are therefore a much sought-after application of nanomedicine. Likewise any other drug delivery system, a number of parameters need to be registered once functionalized NPs are administered, for instance their efficiency in organ-selective targeting, bioaccumulation and excretion. Finally, directin vivoimaging of nanomaterials is an exciting recent field that can provide real-time tracking of those nanocarriers. We review a range of systems suitable forin vivoimaging and monitoring of drug delivery, with an emphasis on most recently introduced molecular imaging modalities based on optical and hybrid contrast, such as fluorescent protein tomography and multispectral optoacoustic tomography. Overall, great potential is foreseen for nanocarriers in medical diagnostics, therapeutics and molecular targeting. A proposed roadmap for ongoing and future research directions is therefore discussed in detail with emphasis on the development of novel approaches for functionalization, targeting and imaging of nano-based drug delivery systems, a cutting-edge technology poised to change the ways medicine is administered.

9 March 2017 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
XDX. L. Deán-Ben
X. L. Deán-Ben
SGS. Gottschalk
S. Gottschalk
BLB. Mc Larney
B. Mc Larney
SSS. Shoham
S. Shoham
DRDaniel Razansky
Daniel Razansky
Visualization of dynamic functional and molecular events in an unperturbed in vivo environment is essential for understanding the complex biology of living organisms and of disease state and progression. To this end, optoacoustic (photoacoustic) sensing and imaging have demonstrated the exclusive capacity to maintain excellent optical contrast and high resolution in deep-tissue observations, far beyond the penetration limits of modern microscopy. Yet, the time domain is paramount for the observation and study of complex biological interactions that may be invisible in single snapshots of living systems. This review focuses on the recent advances in optoacoustic imaging assisted by smart molecular labeling and dynamic contrast enhancement approaches that enable new types of multiscale dynamic observations not attainable with other bio-imaging modalities. A wealth of investigated new research topics and clinical applications is further discussed, including imaging of large-scale brain activity patterns, volumetric visualization of moving organs and contrast agent kinetics, molecular imaging using targeted and genetically expressed labels, as well as three-dimensional handheld diagnostics of human subjects.

16 September 2019 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
NDNeda Davoudi
Neda Davoudi
XDXosé Luís Deán-Ben
Xosé Luís Deán-Ben
DRDaniel Razansky
Daniel Razansky

20 October 2016 in Advances in Optics and Photonics
Verified
Journal Article
Open access
PDF file
SMSrirang Manohar
Srirang Manohar
DRDaniel Razansky
Daniel Razansky
We review the history of photoacoustics from the discovery in 1880 that modulated light produces acoustic waves to the current time, when the pulsed variant of the discovery is fast developing into a powerful biomedical imaging modality. We trace the meandering and fascinating passage of the effect along several conceptual and methodological trajectories to several variants of the method, each with its set of proposed applications. The differences in mechanisms between the intensity modulated effect and the pulsed version are described in detail. We also learn the several names given to the effect, and trace the modern-day divide in nomenclature.